{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:53Z","timestamp":1787009033275,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000313","name":"the British Society for Antimicrobial Chemotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021742","name":"Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cempra"},{"DOI":"10.13039\/100011888","name":"Cerexa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011888","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cubist"},{"name":"GeneSoft"},{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Melinta"},{"DOI":"10.13039\/100019428","name":"Nabriva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oscient"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Replidyne"},{"name":"Rib-X"},{"name":"Theravance"},{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The BSAC Bacteraemia Resistance Surveillance collected isolates from UK and Irish hospitals for central testing. Concurrent UKHSA surveillance collated English hospitals\u2019 own susceptibility data. Results were collated and compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BSAC Surveillance collected quotas of isolates per site annually from 2001 to 2019. MIC testing was by BSAC agar dilution, with resistance mechanisms identified by synergy tests, interpretive reading and PCR. The UKHSA sought hospitals\u2019 data on all bacteraemia isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both surveillance systems recorded dramatic falls in MRSA, from c. 40% of bloodstream Staphylococcus aureus in 2001 to &amp;lt;10% by 2019. Both noted rises in the proportion of MRSA (especially) and MSSA resistant to fusidic acid, along with declines of ciprofloxacin and macrolide resistance amongst MRSA. Methicillin resistance also fell among coagulase-negative staphylococci, albeit only modestly; fusidic acid resistance rose. Shifts for pneumococci were complex, reflecting vaccine-contingent serotype displacements; resistance rates remained low, with high-dose penicillin almost universally active. Enterococcus faecium became more prevalent relative to Enterococcus faecalis; vancomycin resistance averaged 29% among E. faecium versus 2% in E. faecalis, without trend. Erythromycin resistance rose among groups B, C and G (but not group A) streptococci. Oxazolidinones, tigecycline, daptomycin and anti-PBP2\u2032 cephalosporins retained near-universal activity against target species, except that tigecycline has been compromised by breakpoint reductions for streptococci.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gram-positive pathogens were the dominant historical pathogens of bacteraemia. The trends seen here\u2014with many near-universally active antibiotics\u2014indicate little hazard of this situation returning. Nevertheless, few treatments exist in some settings, notably multi-resistant E. faecium endocarditis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf249","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:23:59Z","timestamp":1751873039000},"page":"iv22-iv35","source":"Crossref","is-referenced-by-count":2,"title":["Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019"],"prefix":"10.1093","volume":"80","author":[{"given":"Rosy","family":"Reynolds","sequence":"first","affiliation":[{"name":"Population Health Sciences, University of Bristol , Bristol BS8 2PS ,","place":["UK"]},{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-8332","authenticated-orcid":false,"given":"Shazad","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-6833","authenticated-orcid":false,"given":"Russell","family":"Hope","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Division, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Horner","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiysha","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Adkin","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olisaeloka","family":"Nsonwu","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Division, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Allen","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]},{"name":"Medical Affairs, MSD (UK) Limited , 120 Moorgate, London EC2M 6UR ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-7256","authenticated-orcid":false,"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[{"name":"British Society for Antimicrobial Chemotherapy , 53 Regent Place, Birmingham B1 3NJ ,","place":["UK"]},{"name":"Scientific Affairs, Shionogi B.V. , Fifty Paddington, 50 Eastbourne Terrace, Paddington W2 6LG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Parcell","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital and Medical School , Dundee DD1 9SY ,","place":["UK"]},{"name":"Department of Medical Microbiology, Ninewells Hospital and Medical School , Dundee DD1 9SY ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Livermore","sequence":"additional","affiliation":[{"name":"Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, UK Health Security Agency , Colindale, London NW9 5EQ ,","place":["UK"]},{"name":"Norwich Medical School, University of East Anglia , Norwich NR4 7TJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2025102706022354700_dkaf249-B1","author":"Anon"},{"key":"2025102706022354700_dkaf249-B2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1469-0691.2010.03262.x","article-title":"Trends among pathogens reported as causing bacteraemia in England, 2004\u20132008","volume":"17","author":"Wilson","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2025102706022354700_dkaf249-B3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1128\/CMR.2.4.329","article-title":"Clinical implications of positive blood cultures","volume":"2","author":"Bryan","year":"1989","journal-title":"Clin Microbiol Rev"},{"key":"2025102706022354700_dkaf249-B4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/jac\/dkr561","article-title":"Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10\u2005years","volume":"67","author":"Johnson","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B5","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/jac\/dkp260","article-title":"Voluntary and mandatory surveillance for methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) bacteraemia in England","volume":"64","author":"Pearson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14760584.2018.1413354","article-title":"Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution","volume":"17","author":"Izurieta","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2025102706022354700_dkaf249-B7","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4\u2005years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2025102706022354700_dkaf249-B8","doi-asserted-by":"publisher","first-page":"dlab185","DOI":"10.1093\/jacamr\/dlab185","article-title":"Replacement of Enterococcus faecalis by Enterococcus faecium as the predominant enterococcus in UK bacteraemias","volume":"3","author":"Horner","year":"2021","journal-title":"JAC-Antimicrob Resist"},{"key":"2025102706022354700_dkaf249-B9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijantimicag.2011.12.012","article-title":"Fourteen years in resistance","volume":"39","author":"Livermore","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2025102706022354700_dkaf249-B10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/pathogens13010088","article-title":"Antibiotic resistance to molecules commonly prescribed for the treatment of antibiotic-resistant gram-positive pathogens: what is relevant for the clinician?","volume":"13","author":"Tebano","year":"2024","journal-title":"Pathog Basel Switz"},{"issue":"(Suppl 4)","key":"2025102706022354700_dkaf249-B11","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkaf248","article-title":"The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations","volume":"80","author":"Allen","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B12","author":"Bischoff"},{"key":"2025102706022354700_dkaf249-B13","doi-asserted-by":"publisher","first-page":"acmi000491.v3","DOI":"10.1099\/acmi.0.000491.v3","article-title":"Trends in coagulase-negative staphylococci (CoNS), England, 2010\u20132021","volume":"5","author":"Paranthaman","year":"2023","journal-title":"Access Microbiol"},{"key":"2025102706022354700_dkaf249-B14","doi-asserted-by":"publisher","first-page":"iii7","DOI":"10.1093\/jac\/dkn367","article-title":"Pre-clinical experience with daptomycin","volume":"62","author":"Hawkey","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B15","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.1093\/cid\/cir164","article-title":"Characterization of global patterns and the genetics of fusidic acid resistance","volume":"52","author":"Farrell","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025102706022354700_dkaf249-B16","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1093\/jac\/dkaa306","article-title":"Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data","volume":"75","author":"Horner","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B17","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025102706022354700_dkaf249-B18","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1128\/AAC.36.9.2005","article-title":"Vancomycin resistance gene vanC is specific to Enterococcus gallinarum","volume":"36","author":"Leclercq","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2025102706022354700_dkaf249-B19","author":"Anon"},{"key":"2025102706022354700_dkaf249-B20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/antibiotics12040704","article-title":"Treatment of Enterococcus faecalis infective endocarditis: a continuing challenge","volume":"12","author":"Herrera-Hidalgo","year":"2023","journal-title":"Antibiot Basel Switz"},{"issue":"(Suppl 4)","key":"2025102706022354700_dkaf249-B21","first-page":"iv72","article-title":"Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999\u20132019)","volume":"80","author":"Horner","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B22","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dkx207","article-title":"Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance","volume":"72","author":"Doumith","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B23","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0924-8579(09)70551-5","article-title":"MRSA burden and interventions","volume":"34","author":"Liebowitz","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2025102706022354700_dkaf249-B24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jac\/dkp448","article-title":"Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007","volume":"65","author":"Ellington","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B25","article-title":"European antimicrobial resistance surveillance network (EARS-net)","author":"Anon","journal-title":"Eur Cent Dis Prev Control"},{"key":"2025102706022354700_dkaf249-B26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025102706022354700_dkaf249-B27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1099\/jmm.0.45737-0","article-title":"Erythromycin resistance in invasive serotype 14 pneumococci is highly related to clonal type","volume":"53","author":"Clarke","year":"2004","journal-title":"J Med Microbiol"},{"key":"2025102706022354700_dkaf249-B28","doi-asserted-by":"publisher","first-page":"30423","DOI":"10.2807\/1560-7917.ES.2016.21.50.30423","article-title":"Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014","volume":"21","author":"Sheppard","year":"2016","journal-title":"Euro Surveill"},{"key":"2025102706022354700_dkaf249-B29","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/JCM.01984-06","article-title":"Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus","volume":"45","author":"O\u2019Neill","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2025102706022354700_dkaf249-B30","doi-asserted-by":"publisher","first-page":"e0143106","DOI":"10.1371\/journal.pone.0143106","article-title":"Skin commensal staphylococci may act as reservoir for fusidic acid resistance genes","volume":"10","author":"Hung","year":"2015","journal-title":"PLoS One"},{"key":"2025102706022354700_dkaf249-B31","doi-asserted-by":"publisher","first-page":"1800215","DOI":"10.2807\/1560-7917.ES.2019.24.4.1800215","article-title":"Prospective genomic surveillance of methicillin-resistant Staphylococcus aureus (MRSA) associated with bloodstream infection, England, 1 October 2012 to 30 September 2013","volume":"24","author":"Toleman","year":"2019","journal-title":"Euro Surveill"},{"key":"2025102706022354700_dkaf249-B32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41564-018-0230-7","article-title":"Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis","volume":"3","author":"Lee","year":"2018","journal-title":"Nat Microbiol"},{"key":"2025102706022354700_dkaf249-B33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/jac\/dkg408","article-title":"Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland","volume":"52","author":"Woodford","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025102706022354700_dkaf249-B34","doi-asserted-by":"publisher","first-page":"15033","DOI":"10.1038\/nmicrobiol.2015.33","article-title":"Genome-based characterization of hospital-adapted Enterococcus faecalis lineages","volume":"1","author":"Raven","year":"2016","journal-title":"Nat Microbiol"},{"key":"2025102706022354700_dkaf249-B35","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/S0950268818002285","article-title":"The fall and rise of group A Streptococcus diseases","volume":"147","author":"Barnett","year":"2019","journal-title":"Epidemiol Infect"},{"key":"2025102706022354700_dkaf249-B36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10156-004-0307-5","article-title":"Glycopeptide resistance in Staphylococcus aureus: is it a real threat?","volume":"10","author":"Gemmell","year":"2004","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"2025102706022354700_dkaf249-B37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1099\/00222615-47-10-849","article-title":"Glycopeptide-resistant enterococci: a decade of experience","volume":"47","author":"Woodford","year":"1998","journal-title":"J Med Microbiol"},{"key":"2025102706022354700_dkaf249-B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13073-021-00868-0","article-title":"The global dissemination of hospital clones of Enterococcus faecium","volume":"13","author":"van Hal","year":"2021","journal-title":"Genome Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_4\/iv22\/64943723\/dkaf249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_4\/iv22\/64943723\/dkaf249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:02:48Z","timestamp":1761559368000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/Supplement_4\/iv22\/8301267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf249","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}